Brought to you by 
Blueprint Medicines Corporation
http://www.blueprintmedicines.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Blueprint Medicines Corporation
Keeping Track: Gavreto, Sogroya Bring Annual CDER Novel Approvals To 40; New Analgesic Products Make It Past US FDA
The latest drug approval news and highlights from the Pink Sheet’s US FDA Performance Tracker.
FDA OKs Blueprint/Roche's Gavreto As Rival To Lilly's Retevmo
Regulators in the US have approved Gavreto for metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, setting the stage for a head-to-head battle for market share with Eli Lilly's Retevmo.
EMA Says Yes To GSK’s Belantamab But Rejects Tagraxofusp & Emapalumab
GlaxoSmithKline's first-of-its kind treatment for multiple myeloma is among 11 new medicines that have won an EU approval nod from the European Medicines Agency this week.
GSK's Belantamab Among Drugs Seeking EU Approval Nod
GlaxoSmithKline's potential multiple myeloma treatment is one of several new products that could get an EU marketing thumbs up from the European Medicines Agency this week.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
- Molecular Diversity
-
Drug Discovery Tools